JP2025023920A5 - - Google Patents

Download PDF

Info

Publication number
JP2025023920A5
JP2025023920A5 JP2024180002A JP2024180002A JP2025023920A5 JP 2025023920 A5 JP2025023920 A5 JP 2025023920A5 JP 2024180002 A JP2024180002 A JP 2024180002A JP 2024180002 A JP2024180002 A JP 2024180002A JP 2025023920 A5 JP2025023920 A5 JP 2025023920A5
Authority
JP
Japan
Prior art keywords
antibody
alk5 inhibitor
antigen
binding fragment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024180002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025023920A (ja
JP7798998B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/041291 external-priority patent/WO2020013803A1/en
Application filed filed Critical
Priority to JP2024180002A priority Critical patent/JP7798998B2/ja
Publication of JP2025023920A publication Critical patent/JP2025023920A/ja
Publication of JP2025023920A5 publication Critical patent/JP2025023920A5/ja
Application granted granted Critical
Publication of JP7798998B2 publication Critical patent/JP7798998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024180002A 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用 Active JP7798998B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180002A JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2018/041291 WO2020013803A1 (en) 2018-07-09 2018-07-09 Antibody-alk5 inhibitor conjugates and their uses
JP2021523548A JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2023080821A JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2024180002A JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023080821A Division JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用

Publications (3)

Publication Number Publication Date
JP2025023920A JP2025023920A (ja) 2025-02-19
JP2025023920A5 true JP2025023920A5 (cg-RX-API-DMAC7.html) 2025-02-27
JP7798998B2 JP7798998B2 (ja) 2026-01-14

Family

ID=69142765

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021523548A Active JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2024180002A Active JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体-alk5阻害剤コンジュゲートおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021523548A Active JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体-alk5阻害剤コンジュゲートおよびその使用
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体-alk5阻害剤コンジュゲートおよびその使用

Country Status (7)

Country Link
US (1) US20210299268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820467A4 (cg-RX-API-DMAC7.html)
JP (3) JP7335957B2 (cg-RX-API-DMAC7.html)
CN (2) CN119488607A (cg-RX-API-DMAC7.html)
AU (2) AU2018431586B2 (cg-RX-API-DMAC7.html)
CA (1) CA3104934A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020013803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
AU2018431586B2 (en) * 2018-07-09 2025-03-20 Synthis Therapeutics, Inc Antibody-ALK5 inhibitor conjugates and their uses
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
CN115052663B (zh) * 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
US12668593B2 (en) 2020-09-28 2026-06-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pyrazole compound and preparation method therefor and use thereof
WO2022076905A1 (en) * 2020-10-09 2022-04-14 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN115192731B (zh) * 2021-04-12 2023-09-26 中国科学院上海有机化学研究所 一种抗体药物偶联物的制备方法
AU2023230346A1 (en) * 2022-03-09 2024-10-17 Orum Therapeutics, Inc. Activators of effector t cells
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
EP1539748A1 (en) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN101330914A (zh) 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
SG11201705721WA (en) * 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016115218A1 (en) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
AU2018266103B2 (en) * 2017-05-09 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
AU2018431586B2 (en) 2018-07-09 2025-03-20 Synthis Therapeutics, Inc Antibody-ALK5 inhibitor conjugates and their uses

Similar Documents

Publication Publication Date Title
JP2022046569A5 (cg-RX-API-DMAC7.html)
JP2026010000A5 (cg-RX-API-DMAC7.html)
JP2023512036A5 (cg-RX-API-DMAC7.html)
JP7550768B2 (ja) 抗体-薬物コンジュゲート用のグリコシド含有ペプチドリンカー
JP2022525704A5 (cg-RX-API-DMAC7.html)
JP2021113191A5 (cg-RX-API-DMAC7.html)
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
JP7458997B2 (ja) プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
TWI572361B (zh) 肟共軛至酮修飾多肽的方法
JPWO2022102695A5 (cg-RX-API-DMAC7.html)
JP2023510724A5 (cg-RX-API-DMAC7.html)
TWI618697B (zh) 化合物、連接子-藥物、及配體-藥物耦合體
JP2017537893A5 (cg-RX-API-DMAC7.html)
AU5970900A (en) Method for producing an injectable medicament preparation
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2022547434A5 (cg-RX-API-DMAC7.html)
JP2020506685A5 (cg-RX-API-DMAC7.html)
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2023159335A5 (cg-RX-API-DMAC7.html)
JP2005501052A5 (cg-RX-API-DMAC7.html)
JP2015537045A (ja) ジスルフィドを含むタンパク質から複合体を調製する方法
CN108495840A (zh) γ-鹅膏菌素的衍生物
JP2025506768A5 (cg-RX-API-DMAC7.html)
JP2022533671A5 (cg-RX-API-DMAC7.html)
JP2025512466A5 (cg-RX-API-DMAC7.html)